SEC Company Response from Matinas BioPharma Holdings, Inc. (MTNB) (CIK 0001582554) (MTNB) — Jul 31, 2020

Matinas BioPharma Holdings, Inc. (MTNB) (CIK 0001582554)
Date: July 31, 2020 · CIK: 0001582554 · Accession: 0001493152-20-014325

View on Edgar

AI Filing Summary & Sentiment

Date

July 2, 2020

Author

Chief

Form

CORRESP

Company

Matinas BioPharma Holdings, Inc. (MTNB) (CIK 0001582554)

Letter

Matinas BioPharma Holdings, Inc.

Route 206 South, Suite 302

Bedminster, New Jersey 07921

July 31, 2020

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

F Street, N.E.

Washington, D.C. 20549

Re: Matinas BioPharma Holdings, Inc.

Registration Statement on Form S-3 (File No. 333- 239675)

Filed on July 2, 2020, as subsequently amended on July 27, 2020

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, Matinas BioPharma Holdings Corp. hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 4:00 p.m., Eastern Time, on August 7, 2020, or as soon as practicable thereafter.

Please call Irina Ishak of Lowenstein Sandler LLP at (973) 422-6406 to confirm the effectiveness of the Registration Statement or with any questions.

[Signature page follows.]

U.S. Securities and Exchange Commission

July 31, 2020

Page

Very
truly yours,
MATINAS
BIOPHARMA HOLDINGS, INC.

Show Raw Text

CORRESP
1
filename1.htm

Matinas
BioPharma Holdings, Inc.

1545
Route 206 South, Suite 302

Bedminster,
New Jersey 07921

July
31, 2020

VIA
EDGAR

United
States Securities and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
D.C. 20549

 Re: Matinas
                                         BioPharma Holdings, Inc.

    Registration
                                         Statement on Form S-3 (File No. 333- 239675)

    Filed
                                         on July 2, 2020, as subsequently amended on July 27, 2020

Ladies
and Gentlemen:

In
accordance with Rule 461 under the Securities Act of 1933, as amended, Matinas BioPharma Holdings Corp. hereby requests that the
above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities
and Exchange Commission at 4:00 p.m., Eastern Time, on August 7, 2020, or as soon as practicable thereafter.

Please
call Irina Ishak of Lowenstein Sandler LLP at (973) 422-6406 to confirm the effectiveness of the Registration Statement or with
any questions.

[Signature
page follows.]

U.S.
Securities and Exchange Commission

July
31, 2020

Page
2

    Very
    truly yours,

    MATINAS
    BIOPHARMA HOLDINGS, INC.

    By:
    /s/
    Jerome D. Jabbour

    Name:
    Jerome
    D. Jabbour

    Title:
    Chief
    Executive Officer

    - 2 -

SecProbe.io